Definitive Contract 75N93020C00021
Award Date
6/1/20
Potential Completion Date
5/31/23
Potential Value
$2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Inimmune Corp
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Missoula, MT 59802, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a $4,259,653 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company based in Missoula, Montana. The contract is for the development of a synthetic AS01-like adjuvant system for influenza vaccines. Inimmune Corp has received several previous prime contract awards and sub-contract...
This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
This federal contract award is for the development of UM-1098, a novel synthetic TH17 inducing adjuvant and delivery system. The prime contractor is the University of Montana, and major subcontractors include West Virginia University Research Corporation, Inimmune Corp, and the University of Chicago. The funding agency is the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This is a $10,172,188 definitive cost-no-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Montana for the Vaccine Adjuvant Discovery Program. The contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic CLR-based adjuvants for use with bacterial and fungal antigens to induce durable Th17 and/or Th17/Th1 immunity. The University of Montana will lead the discovery efforts and coordinate...
This is a $3,000,000 firm fixed-price Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Adjuvax LLC, a small disadvantaged and minority-owned business located in Birmingham, Alabama. The contract supports research and development under SBIR Topic 130, which focuses on discovering and down-selecting vaccine adjuvants for infectious and...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Inimmune Corp, a small business biotechnology company, for the "Discovery of New Small Molecule TLR4 Agonists for the Treatment of Allergic Rhinitis". The $631,425.00 Firm Fixed Price contract has a period of performance from July 31, 2018 to July 31, 2020. Inimmune Corp, which has...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
This is a federal contract award from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Adjuvance Technologies Inc. for the preclinical development of a semisynthetic saponin immunological adjuvant called Titerquil-1055 in the context of an influenza vaccine. The contract is a definitive, firm-fixed-price contract with a potential value of $1,471,319.00 and a completion date of December 15, 2020. The contract is...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...